SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
CC
Lv7
55
4325 积分
2021-05-28 加入
最近求助
最近应助
互助留言
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
3天前
已完结
Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy
3天前
已完结
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
3天前
已完结
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort
2个月前
已完结
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial
2个月前
已完结
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
2个月前
已完结
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
2个月前
已完结
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
2个月前
已关闭
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer
2个月前
已完结
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
2个月前
已完结
没有进行任何应助
摘要 不需要【积分已退回】
2个月前
不需要【积分已退回】
1年前
已下载【积分已退回】
1年前
已经下载了【积分已退回】
1年前
不需要【积分已退回】
1年前
你好 附件还有图 麻烦补充一下
1年前
不需要【积分已退回】
1年前
需要的是附件
1年前
已经下载到 谢谢【积分已退回】
2年前
一直显示 现在,等待您上传文献 该求助有驳回情况,建议您浏览应助历史,核实您的应助文件
2年前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论